These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38903713)

  • 41. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome.
    Mahantshetty U; Sturdza A; Naga Ch P; Berger D; Fortin I; Motisi L; Schmid MP; Aravindakshan D; Ghadi Y; Swamidas JV; Chopra S; Gurram L; Nesvacil N; Kirisits C; Pötter R
    Radiother Oncol; 2019 Dec; 141():123-129. PubMed ID: 31495516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel two-step optimization method for tandem and ovoid high-dose-rate brachytherapy treatment for locally advanced cervical cancer.
    Sharma M; Fields EC; Todor DA
    Brachytherapy; 2015; 14(5):613-8. PubMed ID: 26092424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Locally advanced squamous cell cervical cancer in a patient with septate uterus.
    Yavas G; Yavas C; Inan G
    J Contemp Brachytherapy; 2017 Oct; 9(5):487-489. PubMed ID: 29204170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single Application Multifractionated Image Guided Adaptive High-Dose-Rate Brachytherapy for Cervical Cancer: Dosimetric and Clinical Outcomes.
    Mahantshetty U; Gurram L; Bushra S; Ghadi Y; Aravindakshan D; Paul J; Hande V; Pilar A; Chopra S; Ghosh J; Shylasree TS; Popat P; Sable N; Maheswari A; Gupta S
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):826-834. PubMed ID: 34146636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late rectal toxicity determined by dose-volume parameters in computed tomography-based brachytherapy for locally advanced cervical cancer.
    Zhou YC; Zhao LN; Wang N; Hu J; Sun XH; Zhang Y; Li JP; Li WW; Liu JY; Wei LC; Shi M
    Cancer Med; 2016 Mar; 5(3):434-41. PubMed ID: 26806114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of combined intracavitary/interstitial brachytherapy including oblique needles in locally advanced cervix cancer.
    Serban M; Fokdal L; Nielsen SK; Hokland SB; Hansen AT; Spejlborg H; Rylander S; Petric P; Lindegaard JC; Tanderup K
    Brachytherapy; 2021; 20(4):796-806. PubMed ID: 33994344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results.
    Walter F; Maihöfer C; Schüttrumpf L; Well J; Burges A; Ertl-Wagner B; Mahner S; Belka C; Gallwas J; Corradini S
    Brachytherapy; 2018; 17(5):775-781. PubMed ID: 29941345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-dimensional high dose rate intracavitary image-guided brachytherapy for the treatment of cervical cancer using a hybrid magnetic resonance imaging/computed tomography approach: feasibility and early results.
    Beriwal S; Kannan N; Kim H; Houser C; Mogus R; Sukumvanich P; Olawaiye A; Richard S; Kelley JL; Edwards RP; Krivak TC
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):685-90. PubMed ID: 21908180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Commissioning and Dosimetric Results of an Indigenously Developed Intra-Vaginal Template for Interstitial Plus Intracavitary High dose Rate Image-Guided Brachytherapy of Advanced Cervix Cancer.
    Kaliyaperumal V; Banerjee S; Kataria T; Abraham SK; Kamaraj D; Tamilselvan S; Gupta D; Bisht SS; Narang K; Shishak S
    J Med Phys; 2022; 47(4):322-330. PubMed ID: 36908497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early outcomes and impact of a hybrid IC/IS applicator for a new MRI-based cervical brachytherapy program.
    Harkenrider MM; Surucu M; Harmon G; Mysz ML; Shea SM; Yacoub J; Goldberg A; Liotta M; Winder A; Potkul R; Roeske JC; Small W
    Brachytherapy; 2018; 17(1):187-193. PubMed ID: 29089277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical outcomes with MRI-guided image-based brachytherapy in cervical cancer: An institutional experience.
    Simha V; Rai B; Patel FD; Kapoor R; Sharma SC; Singh OA; Singla V; Dhanireddy B; Ghoshal S
    Brachytherapy; 2018; 17(2):345-351. PubMed ID: 29102740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of volume doses from conventional two-dimensional brachytherapy with corresponding doses from three-dimensional magnetic resonance imaging-based brachytherapy in carcinoma cervix.
    Mathews S; Azariah MB; Mohandas S; Menon SV; George P; Jayaprakash PG
    J Cancer Res Ther; 2019; 15(6):1332-1337. PubMed ID: 31898669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data.
    Kashid SR; Gurram L; Pullan S; Chopra S; Mittal P; Ghadi Y; Dheera A; Scaria L; Kohle S; Kadam S; Ghosh J; Rath S; Gupta S; Mahantshetty U
    Brachytherapy; 2024; 23(4):407-415. PubMed ID: 38641455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer.
    Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
    Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
    Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
    Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five-fraction HDR brachytherapy in locally advanced cervical cancer: A monocentric experience.
    Ogorodniitchouk O; Aunier J; Bousarsar A; Lahmamssi C; Sotton S; Ouaz H; Moreno-Acosta P; Moslemi D; Molekzadehmoghani M; Langrand-Escure J; Magne N; Vallard A
    Cancer Radiother; 2021 Jul; 25(5):463-468. PubMed ID: 34023215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes after positron emission tomography/computed tomography-based image-guided brachytherapy for cervical cancer.
    Kim N; Park W; Cho WK; Cho YS
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):743-750. PubMed ID: 35366364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A knowledge-based organ dose prediction tool for brachytherapy treatment planning of patients with cervical cancer.
    Yusufaly TI; Kallis K; Simon A; Mayadev J; Yashar CM; Einck JP; Mell LK; Brown D; Scanderbeg D; Hild SJ; Covele B; Moore KL; Meyers SM
    Brachytherapy; 2020; 19(5):624-634. PubMed ID: 32513446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.